Annexin Pharmaceuticals AB

ANNX · Nasdaq Stockholm · Healthcare

9.16SEK +2.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −67.3%

Performance

1 month

−30.9%

1 year

−67.3%

3 years, per year

−38.3%

5 years, per year

−35.7%

Largest fall, 3 years

−89.6%

Below the peak now

−97.5%

Volatility, 1 year

70.6%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

24.7

Dividend yield

0.0%

Return on equity

−273.6%

Net margin

–

Market value

6 m USD

Quality, value and trend

Where Annexin Pharmaceuticals stands against every Nordic stock today. 100 is best.

Quality72

Profitability and a sound balance sheet over time. Better than 72% of Nordic stocks.

Value0

The price measured against earnings, assets and cash flow. Better than 0% of Nordic stocks.

Trend6

The price development over the past year. Better than 6% of Nordic stocks.

Combined9

Quality, value and trend together. Better than 9% of Nordic stocks.

About Annexin Pharmaceuticals

Annexin Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis